Looks to me that DXCM is in the process of breaking the neckline in a reverse H & S formation. The stock got crushed in '08 with lots of tax loss selling and heavy shorting. The "big boys" are heavily lobbying for 3rd party reimbursement of CGMS, which will significantly benefit Dexcom. Several of the largest players in the category have no continuous monitoring product right now. Obvioulsy, Medtronic and Abbott (2 of the other big guys) felt there was ample reason to move into the area of CGMS, so I believe it is only a matter of time until J&J or Roche make a move for Dexcom.